DINESH

Nephrocare Health Services

Industry: Healthcare
Latest CMP 697
Today's Change ▲ 3.08%
52-Week High / Low 751 | 449
Price Date: 14-Aug-2026
Recommendation Buy
Target Price 1,376
Expected Upside 40.6%
Forecast Horizon 2 Years
Historical CAGR Not Available
1,000 Invested
Today's Value
Investment Period < 5 Years

Stock Snapshot

Post Results Return
+1.0%
Neutral Market Reaction
1-Year Target Price
1,240
2-Year Target Price
1,376
52-Week High / Low
751 / 449
20-Day Return
+10.8%
Market Cap (Cr.)
6,991
Current PE
109.6
P/BV Ratio
6.2
Dividend Yield
Industry PE
57.2

Price Performance

Basis of our Recommendation

Nephrocare Health Services is navigating a period of moderate growth, primarily fueled by its international expansion efforts. Management has indicated that while revenue growth is slowing compared to historical performance, profitability is expected to improve as margins expand, despite recent pressures from a one-off provision. This aligns with Vista's forecast of a stable financial outlook, where revenue growth is projected to moderate but margins are anticipated to improve, supporting a fair valuation. The healthcare sector's current dynamics, characterized by stable pricing power and a shift towards corporate healthcare, further bolster Nephrocare's competitive position. However, the company must remain vigilant regarding margin pressures and regulatory risks that could impact profitability. Over the next 12-24 months, key opportunities include leveraging its international presence and capitalizing on the growing demand for organized tertiary care. Conversely, watchpoints include potential regulatory challenges and the impact of macroeconomic factors such as crude oil prices on operational costs

👍 Why We Like This Stock

  • International expansion is driving moderate revenue growth
  • Management expects profitability to improve as margins expand
  • The healthcare sector's shift towards corporate healthcare presents growth opportunities

Things To Watch Out For

  • Revenue growth is slowing relative to historical performance
  • Margins were recently impacted by a one-off provision
  • Regulatory risks and macroeconomic factors could challenge profitability

Key Parameters

Balance Sheet Strength
Stable Financial Structure
Market Share
Stable
Industry Outlook
Stable
Analyst View
Not Available
Dividend History
No Dividend History
FII Holdings
Reducing

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 566 756 999 1,217 1,463
Profit Before Tax (Cr.) 33 86 97 142 163
PBT Margin 5.8% 11.4% 971.0% 11.7% 11.2%
Net Profit (Cr.) 31 69 62 106 123
Earnings Per Share 3.1 6.9 6.2 10.6 12.2

Analyst Recommendations

Broker Recommendation Target Price Date
ICICI Securities ► Hold 660 22-May-2026
Consensus Recommendation ► None
Consensus Target
Coverage 1 Analysts
Analysts' Viewpoint

Company Overview

Show Company Profile

Nephrocare Health Services Limited operates a chain of kidney care clinics that provides dialysis healthcare services with dialysis centres in India, Uzbekistan, Nepal, Kingdom of Saudi Arabia, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. Nephrocare Health Services Limited was incorporated in 2009 and is based in Hyderabad, India.